Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse

Beardsley "Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats" Psychopharmacology (Berl). (2005) 10.1007/s00213-005-0167-4

[3]

Ben-Jonathan "Dopamine as a prolactin (PRL) inhibitor" Endocr. Rev. (2001) 10.1210/edrv.22.6.0451

[4]

Browne "Novel targets to treat depression: opioid-based therapeutics" Harv. Rev. Psychiatr. (2020) 10.1097/hrp.0000000000000242

[5]

Butelman "Kappa-opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists" Eur. J. Pharmacol. (2001) 10.1016/s0014-2999(01)01121-9

[6]

Cahill "Does the kappa opioid receptor system contribute to pain aversion?" Front. Pharmacol. (2014) 10.3389/fphar.2014.00253

[7]

Carey "Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn" Eur. J. Pharmacol. (2007) 10.1016/j.ejphar.2007.05.007

[8]

Carlezon "Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation" Nat. Protoc. (2007) 10.1038/nprot.2007.441

[9]

Carlezon "Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats" J. Pharmacol. Exp. Therapeut. (2006) 10.1124/jpet.105.092304

[10]

Chambers "A critical review of pentazocine abuse" HSMHA Health Rep. (1971) 10.2307/4594256

[11]

Chartoff "Drug withdrawal conceptualized as a stressor" Behav. Pharmacol. (2014) 10.1097/fbp.0000000000000080

[12]

Chavkin "Dynorphin is a specific endogenous ligand of the kappa opioid receptor" Science (1982) 10.1126/science.6120570

[13]

Chien "(−)-Pentazocine analgesia in mice: interactions with a σ receptor system" Eur. J. Pharmacol. (1995) 10.1016/0014-2999(95)00552-8

[14]

Cross "Subtraction autoradiography of opiate receptor subtypes in human brain" Brain Res. (1987) 10.1016/0006-8993(87)90101-6

[15]

Darcq "Opioid receptors: drivers to addiction?" Nat. Rev. Neurosci. (2018) 10.1038/s41583-018-0028-x

[16]

Di Chiara "Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates: studies with transcerebral dialysis in freely moving rats" Ann. N. Y. Acad. Sci. (1986) 10.1111/j.1749-6632.1986.tb23629.x

[17]

Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

G Di Chiara, A Imperato

Proceedings of the National Academy of Sciences 1988 10.1073/pnas.85.14.5274

[18]

Donzanti "Kappa agonist-induced reduction in dopamine release: site of action and tolerance" Res. Commun. Chem. Pathol. Pharmacol. (1992)

[19]

Ebner "Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens" Psychopharmacology (Berl). (2010) 10.1007/s00213-010-1836-5

[20]

Fava "Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression" Ann. Clin. Psychiatr. (2020)

[21]

Garner "Butorphanol-mediated antinociception in mice: partial agonist effects and mu receptor involvement" J. Pharmacol. Exp. Therapeut. (1997)

[22]

Guerrero "Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140)" J. Med. Chem. (2019) 10.1021/acs.jmedchem.8b01679

[23]

Heal "Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans" Neuropharmacology (2018) 10.1016/j.neuropharm.2018.01.049

[24]

Heel "Butorphanol: a review of its pharmacological properties and therapeutic efficacy" Drugs (1978) 10.2165/00003495-197816060-00001

[25]

Iyengar "Agonist action of the agonist/antagonist analgesic butorphanol on dopamine metabolism in the nucleus accumbens of the rat" Neurosci. Lett. (1987) 10.1016/0304-3940(87)90591-x

[26]

Jacobson "The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice" Psychopharmacology (Berl). (2020) 10.1007/s00213-020-05649-y

[27]

Karkhanis "Dynorphin and its role in alcohol use disorder" Brain Res. (2020) 10.1016/j.brainres.2020.146742

[28]

Knoll "Dynorphin, stress, and depression" Brain Res. (2010) 10.1016/j.brainres.2009.09.074

[29]

Kolesnikov "Peripheral kappa 1-opioid receptor-mediated analgesia in mice" Eur. J. Pharmacol. (1996) 10.1016/0014-2999(96)00520-1

[30]

Koob "Drugs of abuse: anatomy, pharmacology and function of reward pathways" Trends Pharmacol. Sci. (1992) 10.1016/0165-6147(92)90060-j

[31]

Krystal "A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia" Nat. Med. (2020) 10.1038/s41591-020-0806-7

[32]

Lê "Role of κ-opioid receptors in the bed nucleus of stria terminalis in reinstatement of alcohol seeking" Neuropsychopharmacology (2018) 10.1038/npp.2017.120

[33]

MacLean "Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects" Psychopharmacology (Berl). (2013) 10.1007/s00213-012-2912-9

[34]

Maisonneuve "U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats" Neurosci. Lett. (1994) 10.1016/0304-3940(94)90559-2

[35]

Mansour "Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA" Mol. Cell. Neurosci. (1994) 10.1006/mcne.1994.1015

[36]

Margolis "Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology" PLoS One (2020) 10.1371/journal.pone.0232864

[37]

Moustaqim-Barrette "Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review" BMC Publ. Health (2021) 10.1186/s12889-021-10497-2

[38]

Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys

S. Stevens Negus

Psychopharmacology 2004 10.1007/s00213-004-1878-7

[39]

Niwa "Effects of butorphanol and its metabolites on the levels of monoamine and their metabolites in the rat brain. Japan" J. Pharmacol. (1985)

[40]

Nygard "Stress-induced reinstatement of nicotine preference requires dynorphin/kappa opioid activity in the basolateral amygdala" J. Neurosci. (2016) 10.1523/jneurosci.0953-16.2016

[41]

Palandri "An investigation of the reinforcing potential of PN6047 by conditioned place preference testing in rats" College on Problems of Drug Dependence (CPDD) Meeting (2019)

[42]

Paxinos (2006)

[43]

Peachey "Clinical observations of agonist-antagonist analgesic dependence" Drug Alcohol Depend. (1987) 10.1016/0376-8716(87)90008-1

[44]

Pfeiffer "Psychotomimesis mediated by kappa opiate receptors" Science (1986) 10.1126/science.3016896

[45]

Rorick-Kehn "LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders" Neuropharmacology (2014) 10.1016/j.neuropharm.2013.09.021

[46]

Schindler "Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake" J. Neurosci. (2012) 10.1523/jneurosci.3220-12.2012

[47]

Sewell "Antinociceptive activity of narcotic agonist and partial agonist analgesics and other agents in the tail-immersion test in mice and rats" Neuropharmacology (1976) 10.1016/0028-3908(76)90037-x

[48]

Spanagel "The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study" J. Neurochem. (1990) 10.1111/j.1471-4159.1990.tb04963.x

[49]

Tejeda "Dynorphin/kappa-opioid receptor control of dopamine dynamics: implications for negative affective states and psychiatric disorders" Brain Res. (2019) 10.1016/j.brainres.2018.09.023

[50]

Todtenkopf "Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats" Psychopharmacology (Berl) (2004) 10.1007/s00213-003-1680-y

Showing 50 of 61 references

Cited By

5

Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder

Sanjay J. Mathew, Andrew J. Cutler · 2025

Journal of Clinical Psychopharmacol...

Metrics

5

Citations

61

References

Details

Published: Oct 01, 2024
Vol/Issue: 257
Pages: 110037
License: View

Authors

Cite This Article

Filomene G. Morrison, Lori Jean Van Orden, Karla Zeitz, et al. (2024). Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse. Neuropharmacology, 257, 110037. https://doi.org/10.1016/j.neuropharm.2024.110037

Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse

You May Also Like